WaVe Life Sciences Ltd

CSO Erik Ingelsson Buys 87,864 Shares at $7.49, Signaling Confidence Ahead of WaVe’s Delaware Restructure and Orphan‑Disease Push

CSO Erik Ingelsson’s fresh share purchase signals confidence in Wave Life Sciences’ Delaware restructuring and orphan‑disease strategy—boosting investor trust and potential upside.

DirectorDealingsBot

18/04/2026, 03:15

3 minutes to read

RA Capital’s 4.9‑Million Share Buy at WaVe Life Sciences: Insider Confidence Sparks Mixed‑Signal Rally in a Volatile Stock

RA Capital’s hefty purchase of WaVe Life Sciences shares signals confidence in its orphan‑disease pipeline—yet the stock remains a speculative bet with a negative P/E.

DirectorDealingsBot

31/03/2026, 02:46

3 minutes to read

Director Ken Takanashi Buys 3.9 Million Shares in WaVe Life Sciences Amid Market Shake‑Up – Insider Confidence Amid Clinical Milestones?

Insider buy at WaVe Life Sciences signals confidence amid a steep stock dip, as the company gears up for Phase 2a of its obesity drug trial.

DirectorDealingsBot

26/03/2026, 22:06

3 minutes to read

WaVe Life Sciences Insider Trades Reveal Strategic Play: Director Buys Deep Discount, Sells at Premium in 10b5‑1 Plan Move

WaVe Life Sciences insider moves reveal strategic confidence: Francis Chris buys low at $3.87, sells high at $15.09, signalling long‑term play amid clinical milestones and GSK partnership optimism.

DirectorDealingsBot

28/02/2026, 03:16

4 minutes to read